Women’s Health · Clinical trials
Menopausal Vasomotor Symptoms Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About menopausal vasomotor symptoms — and why its trials are hard
Vasomotor symptoms (VMS) - hot flushes and night sweats - are the hallmark of menopause, affecting up to 80% of women and often persisting for years, disrupting sleep, mood, cognition and quality of life. Menopausal hormone therapy (systemic oestrogen, with a progestogen when the uterus is intact) remains the most effective treatment, but contraindications, risk perceptions and patient preference create major demand for non-hormonal options. Low-dose paroxetine (Brisdelle) was the first FDA-approved non-hormonal therapy. A mechanistic breakthrough came from targeting hypertrophied KNDy neurons in the hypothalamic thermoregulatory centre: fezolinetant (Veozah), a neurokinin-3 (NK3) receptor antagonist, was FDA-approved in 2023 after the SKYLIGHT programme, and the dual NK1/NK3 antagonist elinzanetant (Lynkuet) was approved in 2025 after the OASIS trials. These agents reduce hot-flush frequency and severity without hormonal exposure. Endpoints centre on daily frequency and severity of moderate-to-severe hot flushes. Remaining needs include long-term safety, hepatic monitoring for fezolinetant, and options for women with limited response.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Fezolinetant (Veozah) | 2023 | Moderate-to-severe vasomotor symptoms due to menopause (non-hormonal NK3 receptor antagonist) | SKYLIGHT 1 (Lancet 2023) and SKYLIGHT 2 (JCEM 2023) | Mean change from baseline in frequency and severity of moderate-to-severe VMS at weeks 4 and 12 | SKYLIGHT 2 week-12 least-squares mean difference vs placebo: frequency -2.53 episodes/day and severity -0.29 (both P<0.001) |
| Elinzanetant (Lynkuet) | 2025 | Moderate-to-severe vasomotor symptoms due to menopause (dual NK1/NK3 receptor antagonist) | OASIS 1, OASIS 2 (JAMA 2024) and OASIS 3 | Mean change from baseline in frequency and severity of moderate-to-severe VMS at weeks 4 and 12 | Statistically significant reductions in VMS frequency and severity vs placebo at weeks 4 and 12 (P<0.001); OASIS 1/2 showed clinically meaningful improvement over placebo (exact LS mean differences unverified) |
| Paroxetine mesylate (low dose 7.5 mg) (Brisdelle) | 2013 | Moderate-to-severe vasomotor symptoms associated with menopause (first non-hormonal FDA approval) | Two phase 3 randomized placebo-controlled trials | Reduction in frequency and severity of moderate-to-severe hot flushes vs placebo | Modest but statistically significant reduction of roughly 0.5-1.6 fewer hot flushes per day vs placebo (unverified exact values) |
| Conjugated oestrogens / estradiol (menopausal hormone therapy) (Premarin / multiple) | 1942 | Moderate-to-severe vasomotor symptoms (most effective therapy; add progestogen if uterus intact) | Numerous randomized controlled trials and Cochrane meta-analyses | Reduction in frequency and severity of hot flushes | Approximately 75% reduction in hot-flush frequency vs placebo in pooled analyses |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in menopausal vasomotor symptoms development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Pavinetant (MLE4901/AZD4901, NK3 receptor antagonist) — Phase 2 program (Prague et al., Lancet 2017) | Efficacy demonstrated but clinical development discontinued | Dose-dependent elevations in liver transaminases (hepatotoxicity signal) halted advancement, although the class was validated by later NK3 antagonists |
| Gabapentin (for VMS indication) — Phase 3 (Breeze) extended-release gabapentin trials | Did not gain FDA approval for the VMS indication | Efficacy was modest and tolerability (somnolence, dizziness) limited the benefit-risk case relative to available options; used off-label only |
Choosing the right endpoint
Primary endpoints that matter in menopausal vasomotor symptoms trials
- VMS frequency — Mean change from baseline in the number of moderate-to-severe hot flushes per day, a co-primary regulatory endpoint (weeks 4 and 12)
- VMS severity — Mean change in a weighted severity score of hot flushes, the second co-primary endpoint
- Sleep disturbance — Patient-reported sleep (e.g., PROMIS Sleep Disturbance) capturing night-sweat burden; key for dual NK1/NK3 antagonists
- Quality of life — Menopause-specific quality-of-life instruments (e.g., MENQOL) assessing overall symptom impact
- Hepatic transaminases — Safety endpoint; fezolinetant requires baseline and periodic liver monitoring given transaminase elevation risk
How iNGENū runs menopausal vasomotor symptoms trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Menopausal Vasomotor Symptoms clinical trials — FAQs
How do NK3 antagonists relieve hot flushes?
Is hormone therapy still the most effective option?
Does fezolinetant require monitoring?
Ready to discuss your menopausal vasomotor symptoms trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal